Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

Metabolic dysfunction-associated steatotic liver disease, or MASLD, is an umbrella term describing conditions related to a ...

The actor said he lost 40 pounds taking GLP-1 medication before a negative side effect necessitated a change to a different ...

The approval adds a new indication for GLP-1 drugs and gives Novo an advantage over Lilly’s rival diabetes drug Mounjaro, ...

The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...

During his appearance on the " Armchair Expert " podcast on Monday, the "Frozen" actor opened up about taking weight loss ...

My parents are both retired medical professionals who are in their early 70s. My father has diabetes that he manages with medication, and he also has a history of recurrent prostate cancer. My mother ...

Winfrey opened up about her decision to use a medication to help her lose weight in an interview with People. Her new TV ...

The FDA has approved a new indication for semaglutide to lower the risk for worsening kidney disease, kidney failure and cardiovascular death among adults with type 2 diabetes and chronic kidney ...

Novo Nordisk (NVO) said its popular diabetes drug Ozempic, or semaglutide, has been approved for the treatment of patients ...

Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...